• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
[Predicting the 3-year tumor-specific survival in patients with T non-metastatic renal cell carcinoma].[预测T期非转移性肾细胞癌患者的3年肿瘤特异性生存率]
Beijing Da Xue Xue Bao Yi Xue Ban. 2024 Aug 18;56(4):673-679. doi: 10.19723/j.issn.1671-167X.2024.04.021.
2
Development and validation of a nomogram to predict postoperative cancer-specific survival of patients with nonmetastatic T3a renal cell carcinoma.制定并验证一种列线图模型,以预测无远处转移 T3a 期肾细胞癌患者的术后癌症特异性生存情况。
Urol Oncol. 2021 Dec;39(12):835.e19-835.e27. doi: 10.1016/j.urolonc.2021.06.014. Epub 2021 Oct 4.
3
[Establishment and validation of a novel nomogram to predict overall survival after radical nephrectomy].[一种预测根治性肾切除术后总生存期的新型列线图的建立与验证]
Zhonghua Zhong Liu Za Zhi. 2023 Aug 23;45(8):681-689. doi: 10.3760/cma.j.cn112152-20221027-00722.
4
Prognostic nomograms and Aggtrmmns scoring system for predicting overall survival and cancer-specific survival of patients with kidney cancer.用于预测肾癌患者总生存期和癌症特异性生存期的预后列线图及Aggtrmmns评分系统。 需注意,原文中的“Aggtrmmns”可能有误,不太明确其准确含义。
Cancer Med. 2020 Apr;9(8):2710-2722. doi: 10.1002/cam4.2916. Epub 2020 Feb 22.
5
Development and validation of a nomogram to predict overall survival for patients with metastatic renal cell carcinoma.开发和验证用于预测转移性肾细胞癌患者总生存期的列线图。
BMC Cancer. 2020 Nov 4;20(1):1066. doi: 10.1186/s12885-020-07586-7.
6
Prognostic value of preoperative combined neutrophil, monocyte, and lymphocyte scores in patients with renal cell carcinoma undergoing laparoscopic nephrectomy: A retrospective study.术前联合中性粒细胞、单核细胞和淋巴细胞评分对接受腹腔镜肾切除术的肾癌患者的预后价值:一项回顾性研究。
Cancer Med. 2024 May;13(9):e7214. doi: 10.1002/cam4.7214.
7
Development and validation of prognostic nomograms for adult with papillary renal cell carcinoma: A retrospective study.开发和验证成人肾乳头状细胞癌预后列线图:一项回顾性研究。
Clinics (Sao Paulo). 2024 May 7;79:100374. doi: 10.1016/j.clinsp.2024.100374. eCollection 2024.
8
Prognostic Factors and a Nomogram Predicting Overall Survival and Cancer-Specific Survival for Patients with Collecting Duct Renal Cell Carcinoma.预测肾集合管细胞癌患者总生存和癌症特异性生存的预后因素和列线图。
Biomed Res Int. 2021 Nov 11;2021:6736008. doi: 10.1155/2021/6736008. eCollection 2021.
9
A Nomogram Including Sarcopenia for Predicting Progression-Free Survival in Patients with Localized Papillary Renal Cell Carcinoma: A Retrospective Cohort Study.一项包含肌肉减少症的列线图用于预测局限性乳头状肾细胞癌患者无进展生存期:一项回顾性队列研究
Ann Surg Oncol. 2024 Sep;31(9):5815-5826. doi: 10.1245/s10434-024-15666-2. Epub 2024 Jul 1.
10
Two web-based dynamically interactive nomograms and risk stratification systems for predicting survival outcomes and guiding treatment in non-metastatic nasopharyngeal carcinoma.用于预测非转移性鼻咽癌生存结局并指导治疗的两个基于网络的动态交互式列线图和风险分层系统。
J Cancer Res Clin Oncol. 2023 Nov;149(17):15969-15987. doi: 10.1007/s00432-023-05363-0. Epub 2023 Sep 8.

本文引用的文献

1
Partial versus radical nephrectomy for the treatment of pT3aN0M0 renal cell carcinoma: A propensity score analysis.部分切除术与根治性切除术治疗 pT3aN0M0 期肾细胞癌:倾向评分分析。
Asian J Surg. 2023 Sep;46(9):3607-3613. doi: 10.1016/j.asjsur.2023.04.058. Epub 2023 May 3.
2
Differential Prognostic Value of Extrarenal Involvement in Patients With Non-Metastatic Renal Cell Cancer.非转移性肾细胞癌患者肾外侵犯的预后差异。
Clin Genitourin Cancer. 2023 Aug;21(4):e279-e285.e1. doi: 10.1016/j.clgc.2023.02.008. Epub 2023 Feb 25.
3
Comparison of Long-term Outcomes for Young and Healthy Patients with cT1a and cT3a Renal Cell Carcinoma Treated with Partial Nephrectomy.接受部分肾切除术治疗的cT1a和cT3a期年轻健康肾细胞癌患者的长期预后比较。
Eur Urol Focus. 2023 Mar;9(2):333-335. doi: 10.1016/j.euf.2022.09.018. Epub 2022 Oct 12.
4
Development and validation of a nomogram to predict postoperative cancer-specific survival of patients with nonmetastatic T3a renal cell carcinoma.制定并验证一种列线图模型,以预测无远处转移 T3a 期肾细胞癌患者的术后癌症特异性生存情况。
Urol Oncol. 2021 Dec;39(12):835.e19-835.e27. doi: 10.1016/j.urolonc.2021.06.014. Epub 2021 Oct 4.
5
A meta-analysis for comparison of partial nephrectomy radical nephrectomy in patients with pT3a renal cell carcinoma.一项比较pT3a期肾细胞癌患者行部分肾切除术与根治性肾切除术的荟萃分析。
Transl Androl Urol. 2021 Mar;10(3):1170-1178. doi: 10.21037/tau-20-1262.
6
Update on the Role of Imaging in Clinical Staging and Restaging of Renal Cell Carcinoma Based on the AJCC 8th Edition, From the Special Series on Cancer Staging.基于第 8 版 AJCC 的肾癌临床分期和再分期中影像学作用的更新,选自癌症分期特刊。
AJR Am J Roentgenol. 2021 Sep;217(3):541-555. doi: 10.2214/AJR.21.25493. Epub 2021 Mar 24.
7
Comparison of oncologic outcomes between partial nephrectomy and radical nephrectomy in patients who were upstaged from cT1 renal tumor to pT3a renal cell carcinoma: an updated systematic review and meta-analysis.cT1期肾肿瘤升级为pT3a期肾细胞癌患者行部分肾切除术与根治性肾切除术的肿瘤学结局比较:一项更新的系统评价和荟萃分析
Ther Adv Urol. 2020 Dec 25;12:1756287220981508. doi: 10.1177/1756287220981508. eCollection 2020 Jan-Dec.
8
The critical impact of tumor size in predicting cancer special survival for T3aM0M0 renal cell carcinoma: A proposal of an alternative T3aN0M0 stage.肿瘤大小对 T3aM0M0 肾细胞癌癌症特异性生存预测的关键影响:提出一种替代 T3aN0M0 分期的方案。
Cancer Med. 2021 Jan;10(2):605-614. doi: 10.1002/cam4.3629. Epub 2020 Dec 6.
9
Partial nephrectomy provides equivalent oncologic outcomes and better renal function preservation than radical nephrectomy for pathological T3a renal cell carcinoma: A meta-analysis.部分肾切除术与根治性肾切除术相比,可为病理 T3a 肾细胞癌患者提供等效的肿瘤学结果并更好地保留肾功能:一项荟萃分析。
Int Braz J Urol. 2021 Jan-Feb;47(1):46-60. doi: 10.1590/S1677-5538.IBJU.2020.0167.
10
Prognostic evaluation of perinephric fat, renal sinus fat, and renal vein invasion for patients with pathological stage T3a clear-cell renal cell carcinoma.评价肾周脂肪、肾窦脂肪和肾静脉侵犯对病理 T3a 期透明细胞肾细胞癌患者的预后价值。
BJU Int. 2019 Feb;123(2):270-276. doi: 10.1111/bju.14523. Epub 2018 Sep 9.

[预测T期非转移性肾细胞癌患者的3年肿瘤特异性生存率]

[Predicting the 3-year tumor-specific survival in patients with T non-metastatic renal cell carcinoma].

作者信息

Zhou Zezhen, Deng Shaohui, Yan Ye, Zhang Fan, Hao Yichang, Ge Liyuan, Zhang Hongxian, Wang Guoliang, Zhang Shudong

机构信息

Department of Urology, Peking University Third Hospital, Beijing 100191, China.

出版信息

Beijing Da Xue Xue Bao Yi Xue Ban. 2024 Aug 18;56(4):673-679. doi: 10.19723/j.issn.1671-167X.2024.04.021.

DOI:10.19723/j.issn.1671-167X.2024.04.021
PMID:39041564
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11284467/
Abstract

OBJECTIVE

To predict the 3-year cancer-specific survival (CSS) of patients with non-metastatic T renal cell carcinoma after surgery.

METHODS

A total of 336 patients with pathologically confirmed T N0-1M0 renal cell carcinoma (RCC) who underwent surgical treatment at the Department of Urology, Peking University Third Hospital from March 2013 to February 2021 were retrospectively collected. The patients were randomly divided into a training cohort of 268 cases and an internal validation cohort of 68 cases at an 4 ∶ 1 ratio. Using two-way Lasso regression, variables were selected to construct a nomogram for predicting the 3-year cancer-specific survival (CSS) of the patients with TN0-1M0 RCC. Performance assessment of the nomogram included evaluation of discrimination and calibration ability, as well as clinical utility using measures such as the concordance index (C-index), time-dependent area under the receiver operating characteristic curve [time-dependent area under the curve (AUC)], calibration curve, and decision curve analysis (DCA). Risk stratification was determined based on the nomogram scores, and Kaplan-Meier survival analysis and Log-rank tests were employed to compare progression-free survival (PFS) and cancer-specific survival (CSS) among the patients in the different risk groups.

RESULTS

Based on the Lasso regression screening results, the nomogram was constructed with five variables: tumor maximum diameter, histological grading, sarcomatoid differentiation, T feature, and lymph node metastasis. The baseline data of the training and validation sets showed no statistical differences (>0.05). The consistency indices of the column diagram were found to be 0.808 (0.708- 0.907) and 0.903 (0.838-0.969) for the training and internal validation sets, respectively. The AUC values for 3-year cancer-specific survival were 0.843 (0.725-0.961) and 0.923 (0.844-1.002) for the two sets. Calibration curves of both sets demonstrated a high level of consistency between the actual CSS and predicted probability. The decision curve analysis (DCA) curves indicated that the column diagram had a favorable net benefit in clinical practice. A total of 336 patients were included in the study, with 35 cancer-specific deaths and 69 postoperative recurrences. According to the line chart, the patients were divided into low-risk group (scoring 0-117) and high-risk group (scoring 119-284). Within the low-risk group, there were 16 tumor-specific deaths out of 282 cases and 36 postoperative recurrences out of 282 cases. In the high-risk group, there were 19 tumor-specific deaths out of 54 cases and 33 post-operative recurrences out of 54 cases. There were significant differences in progression-free survival (PFS) and cancer-specific survival (CSS) between the low-risk and high-risk groups ( < 0.000 1).

CONCLUSION

A nomogram model predicting the 3-year CSS of non-metastatic T renal cell carcinoma patients was successfully constructed and validated in this study. This nomogram can assist clinicians in accurately assessing the long-term prognosis of such patients.

摘要

目的

预测非转移性T期肾细胞癌患者术后3年癌症特异性生存率(CSS)。

方法

回顾性收集2013年3月至2021年2月在北京大学第三医院泌尿外科接受手术治疗的336例经病理确诊的T N0-1M0肾细胞癌(RCC)患者。患者按4∶1比例随机分为268例的训练队列和68例的内部验证队列。采用双向套索回归选择变量,构建预测TN0-1M0 RCC患者3年癌症特异性生存率(CSS)的列线图。列线图的性能评估包括辨别力和校准能力评估,以及使用一致性指数(C指数)、受试者操作特征曲线的时间依赖性曲线下面积[时间依赖性曲线下面积(AUC)]、校准曲线和决策曲线分析(DCA)等指标进行临床实用性评估。根据列线图评分进行风险分层,采用Kaplan-Meier生存分析和Log-rank检验比较不同风险组患者的无进展生存期(PFS)和癌症特异性生存期(CSS)。

结果

根据套索回归筛选结果,构建了包含肿瘤最大直径、组织学分级、肉瘤样分化、T特征和淋巴结转移5个变量的列线图。训练集和验证集的基线数据无统计学差异(>0.05)。训练集和内部验证集列线图的一致性指数分别为0.808(0.708-0.907)和0.903(0.838-0.969)。两组3年癌症特异性生存率的AUC值分别为0.843(0.725-0.961)和0.923(0.844-1.002)。两组的校准曲线均显示实际CSS与预测概率之间具有高度一致性。决策曲线分析(DCA)曲线表明列线图在临床实践中具有良好的净效益。本研究共纳入336例患者,其中35例癌症特异性死亡,69例术后复发。根据线图,患者分为低风险组(评分0-117)和高风险组(评分119-284)。低风险组282例中有16例肿瘤特异性死亡,282例中有36例术后复发。高风险组54例中有19例肿瘤特异性死亡,54例中有33例术后复发。低风险组和高风险组之间的无进展生存期(PFS)和癌症特异性生存期(CSS)存在显著差异(<0.000 1)。

结论

本研究成功构建并验证了预测非转移性T期肾细胞癌患者3年CSS的列线图模型。该列线图可协助临床医生准确评估此类患者的长期预后。